key: cord-0975248-qygvlkcj authors: Song, Xiaoyu; Ji, Jiayi; Reva, Boris; Joshi, Himanshu; Calinawan, Anna Pamela; Mazumdar, Madhu; Wisnivesky, Juan P.; Taioli, Emanuela; Wang, Pei; Veluswamy, Rajwanth R. title: Post-anticoagulant D-dimer is a highly prognostic biomarker of COVID-19 mortality date: 2021-03-05 journal: ERJ Open Res DOI: 10.1183/23120541.00018-2021 sha: d1d46a4f4cf65ab28a006fdfc409ee56464a6302 doc_id: 975248 cord_uid: qygvlkcj RESEARCH QUESTION: Clinical biomarkers that accurately predict mortality are needed for the effective management of patients with severe COVID-19 illness. In this study, we determine whether changes in D-dimer levels after anticoagulation are independently predictive of in-hospital mortality. STUDY DESIGN: Adult patients hospitalised for severe COVID-19 who received therapeutic anticoagulation for thromboprophylaxis were identified from a large COVID-19 database of the Mount Sinai Health System in New York City. We studied the ability of post-anticoagulant D-dimer levels to predict in-hospital mortality, while taking into consideration 65 other clinically important covariates including patient demographics, comorbidities, vital signs and several laboratory tests. RESULTS: 1835 adult patients with PCR-confirmed COVID-19 who received therapeutic anticoagulation during hospitalisation were included. Overall, 26% of patients died in the hospital. Significantly different in-hospital mortality rates were observed in patient groups based on mean D-dimer levels and trend following anticoagulation: 49% for the high mean-increase trend (HI) group; 27% for the high-decrease (HD) group; 21% for the low-increase (LI) group; and 9% for the low-decrease (LD) group (p<0.001). Using penalised logistic regression models to simultaneously analyze 67 clinical variables, the HI (adjusted odds ratios [ORadj]: 6.58, 95% CI 3.81–11.16), LI (ORadj: 4.06, 95% CI 2.23–7.38) and HD (ORadj: 2.37; 95% CI 1.37–4.09) D-dimer groups (reference: LD group) had the highest odds for in-hospital mortality among all clinical features. CONCLUSION: Changes in D-dimer levels and trend following anticoagulation are highly predictive of in-hospital mortality and may help guide resource allocation and future studies of emerging treatments for severe COVID-19. The COVID-19 pandemic has resulted in 46 million confirmed cases and 1.2 million deaths worldwide through November, 2020 1 However, while D-dimer measurements generally are followed throughout the hospitalization, there remains no consensus or guidance as to how changes in D-dimer levels should be interpreted following anticoagulant therapy in COVID-19 patients. In this study, we hypothesized that changes in D-dimer levels and trends following administration of therapeutic doses of anticoagulation in patients with severe infections are predictive of in-hospital mortality. To determine the role of D-dimer in this setting, we leveraged a large institutional database of COVID-19 hospitalized patients from the Mount Sinai Health System (MSHS) in New York City, one of the initial epicenters of the COVID-19 pandemic in the United States (US). York City, serving a diverse patient population with high representation of low-income minorities. This study utilized a comprehensive COVID-19 database, which includes deidentified clinical data extracted from the electronic medical records of all patients tested for and/or diagnosed with COVID-19 within the health system from February 25, 2020 to May 31, 2020. We included all adults (≥18 years of age) who were hospitalized for a new COVID-19 infection (based on RT-PCR COVID-19 assay using nasopharyngeal swabs), and were treated with therapeutic doses of anticoagulation for thromboprophylaxis. Included patients required follow up data for at least 3 days after the first anticoagulant dose and information on their hospitalization outcome (discharged vs. deceased). We then excluded patients who: 1) had high risk of bleeding from therapeutic doses of anticoagulation due to either low platelet counts (<50,000/uL) or elevated international normalization ratio (INR>1.5) and 2) were given therapeutic doses of anticoagulation or tissue plasminogen activator (TPA) for a newly diagnosed VTE as large vessel thrombosis could affect post-anticoagulant D-dimer levels. For each patient, we obtained baseline sociodemographic data (i.e., age, sex, selfreported race and ethnicity), smoking status, body mass index (BMI), and 18 common comorbidities (Table S1 ). Baseline vital signs (temperature, systolic blood pressure, diastolic blood pressure, oxygen saturation, heart rate, respiratory rate) and laboratory tests obtained within 24 hours of admission and prior to receiving anticoagulation were collected. In cases where multiple vital signs were recorded during the first 24 hours of admission, we used the most clinically abnormal measurement concerning for systemic inflammatory response syndrome (SIRS) 11 . A preprocessing procedure was performed to exclude laboratory tests that were missing in > 50% of patients. The remaining 35 laboratory tests that were used for analysis included complete blood count (CBC) with differential, comprehensive metabolic panel (CMP), inflammatory markers (i.e., ferritin, C-reactive protein [CRP], lactate dehydrogenase [LDH]), liver function tests and baseline D-dimer. All together, 65 baseline variables were considered for each patient (Table S1 ). The MSHS, alongside many other high acuity hospitals, has developed a standardized protocol for anticoagulant therapy in patients requiring hospital admission for COVID-19. We recorded post-anticoagulant D-dimer levels as all measurements collected within the first 3 days after the administration of therapeutic doses of anticoagulation was started. This time frame was chosen after finding the incremental Area under the Curve (AUC) change for the predictive capability of our model was not significantly different for each additional day of D-dimer levels past day 3 ( Figure S1 ). As the number of D-dimer measurements during this period varied dramatically (from 0 to 18 measurements) for each patient, we calculated both the mean and trend to summarize the data. The trend was defined, if at least 2 measurements were available, as the slope of a linear The study endpoint is a binary indicator of in-hospital mortality, defined as patients who died during their admission vs. patients who were discharged alive from the hospital, usually to home, nursing facility, acute/sub-acute rehab or long-term care facility. To test the associations between baseline and post-anticoagulant D-dimer variables We assessed whether the in-hospital mortality and the baseline characteristics of patients differed across the four D-dimer groups described above. tests were used for categorical variables and Kruskal-Wallis tests for continuous variables. Variables that passed 5% significance level after Bonferroni correction were further examined for statistically significant differences in groups with high D-dimer levels (HI and HD combined) vs. groups with low D-dimer levels (LI and LD combined); as well as in groups with increasing D-dimer vs. those with decreasing D-dimer trends (HI vs. HD; LI vs. LD). We assessed the predictivity of D-dimers for in-hospital mortality conditional on baseline characteristics of patients. To better estimate effect sizes of predictors, we randomly split the samples into discovery and validation subsets with equal sizes and performed variable selection on the discovery subset while inference of effect sizes on the validation subset to avoid post-selection inference, which results in biased estimates and confidence intervals (CIs). In the discovery subset, we utilized regularized logistic regression models with Lasso penalty 13 to select the most important predictors for inhospital mortality from a large feature set of 67 important clinical variables (Table S1) . For the variables selected by the penalized logistic regressions, we performed an ordinary logistic regression using the validation subset to estimate odds ratios (ORs) and the corresponding 95% CIs. For the variables that were confirmed to be statistically significant, we calculated AUC differences between leave-one-predictor-out models and the full model in the validation subset to assess the relative importance of each predictor. Moreover, we performed parallel analyses using only baseline variables, and compared the predictive performance of these models with the above ones using postanticoagulant D-Dimer information in the validation subset. We compared the 10-fold cross-validation prediction AUCs between the baseline model and the full model with post-anticoagulant D-dimer groups among 100 randomly selected bootstrap samples. All statistical analyses were repeated in complete case analysis among samples without missing post-anticoagulant D-dimer data, with similar results (Table S3) . We analyzed a subset of 668 patients in our cohort that had at least two postanticoagulant fibrinogen measurements in order to determine if changes in D-Dimer levels reflected onset of disseminated intravascular coagulopathy (DIC) or if a more COVID-specific process. As fibrinogen would not be affected by anticoagulation directly, we used the mean and trend as a proxy for DIC and added these covariates in the penalized logistic regression. After applying the selection criteria to the COVID-19 database (n=65,501 Tables 1 and S1 ). After beginning therapeutic doses of anticoagulation, the mean D-dimer was significantly higher for patients who died vs. those who were discharged from the (Table S2) . Among patients within the high or low mean post-anticoagulant D-dimer groups, only lower baseline D-dimer was associated with increasing D-dimer trends (p<0.001) ( Figure 3B ). Jointly modeling post-anticoagulant D-dimer groups and 65 baseline covariates with penalized logistic regressions, 12 variables were selected to be predictive of in-hospital mortality through 10-fold cross validation based on the discovery subset. Among these, based on the validation subset ( Figure 4A ). Compared to patients in the LD post- Figure 4A ). The baseline D-dimer value was not a significant predictor of mortality and was not selected in the final model. Additionally, we found consistent results that post-anticoagulant D-Dimer remained the most significant predictor of in-hospital mortality after adjusting for fibrinogen ( Figure S2 ). patients. However, there is no consensus on how to interpret changes in D-dimer levels in this context 15 . We found that the ability of D-dimer to predict in-hospital mortality was not affected by fibrinogen levels, indicating the hypercoagulability is the result of a more COVID-specific process rather than DIC. Once on therapeutic doses of anticoagulation, elevated D-dimer levels could be expected to decrease or normalize reflecting the cessation of new clot formation. However, persistently elevated or rising D-dimer levels following anticoagulation in COVID-19 patients may signify continued risk of large vessel thrombotic events 16, 17 . In a study of 608 patients who completed anticoagulation for VTE, patients with persistently elevated D-dimer levels were 2.27 fold more likely to experience recurrent VTE than those who had normalization of D-dimer 16 World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report -209 Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19 Clinical Characteristics of Coronavirus Disease 2019 in China Venous Thromboembolism among Hospitalized Patients with COVID-19 Undergoing Thromboprophylaxis: A Systematic Review and Meta-Analysis Thromboelastography Profiles of Critically Ill Patients With Coronavirus Disease High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients Systemic inflammatory response syndrome (SIRS): where did it come from and is it still relevant today? Multivariate imputation by chained equations in R Statistical Learning with Sparsity: The Lasso and Generalizations Elevated D-Dimer Levels are Associated with Increased Risk of Mortality in COVID-19: A Systematic Review and Meta-Analysis COVID-19 and D-dimer: Frequently Asked Questions D-dimer testing to determine the duration of anticoagulation therapy The prediction role of D-dimer in recurrence of venous thromboembolism 1-year after anticoagulation discontinuing following idiopathic deep vein thrombosis Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19 Remdesivir for the Treatment of Covid-19 -Final Report Convalescent plasma as a potential therapy for COVID-19 Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report